FY2022 Q3 Financial and R&D Update

ENHERTUⓇ Progression-Free Survival Probability, % DESTINY-Breast03 Study SABCS 2022 Efficacy (PFS) Efficacy (OS) T-DXd T-DM1 T-DXd T-DM1 100- Median (95% CI), months 28.8 (22.4-37.9) 6.8 (5.6-8.2) T-DXd: 94.1% (95% CI, 90.4-96.4) T-DM1: 86.0% (95% CI, 81.1-89.8) 100- 80 T-DXd: 75.2% (95% CI, 69.3-80.2) T-DM1: 33.9% (95% CI, 27.7-40.2) HR P 0.33 (95% CI, 0.26-0.43) <0.000001a,b T-DXd: 53.7% (95% CI, 46.8-60.1) T-DM1: 26.4% (95% CI, 20.5-32.6) 60 40 ++ 20 0 1 Censor T-DXD (n = 261) T-DM1 (n = 263) 2 3 4 5 67 8 Overall Survival Probability,% T-DXd: 77.4% (95% CI, 71.7-82.1) T-DM1: 69.9% (95% CI, 63.7-75.2) Median (95% CI), months NR (40.5-NE) NR (34.0-NE) 80- HR P 0.64 (95% CI, 0.47-0.87) 0.0037a,b 60 40 0 Censor T-DXd (n = 261) T-DM1 (n = 263) 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 Anti-cancer therapies in post trial setting: T-DXd arm: 64/182 (35.2%) received T-DM1 ⚫ T-DM1 arm: 42/243 (17.3%) received T-DXd 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 Time, months DESTINY-Breast03 Study Time, months Comparative study of ENHERTUⓇ and T-DM1 as a 2nd line treatment in patients with HER2 positive recurrent metastatic BC ENHERTUⓇ reduced the risk of death by 36% (HR: 0.64) ■mPFS with ENHERTUⓇ was 4 times longer than with T-DM1 (28.8 months vs. 6.8 months) ■ORR was 78.5%; 1 in 5 (21%) patients experienced CR Data Cutoff: July 25, 2022 The safety profile observed with ENHERTU® in DESTINY-Breast03 was consistent with previous clinical trials with no new safety concerns identified Groundbreaking survival supports ENHERTUⓇ as the 2L SOC in HER2+ BC BC: breast cancer, Cl: confidence interval, CR: complete response, HR: hazard ratio, ILD: interstitial lung disease, mPFS: median progression-free survival, ORR: objective response rate, OS: overall survival, PFS: progression-free survival, NE: not estimable, NR: not reached, SABCS: San Antonio Breast Cancer Symposium, SOC: standard of care, T-DM1: trastuzumab emtansine, T-DXd: trastuzumab deruxtecan Daiichi-Sankyo 19

View entire presentation